A Brown University-led trial published in Nature Biomedical Engineering demonstrates simultaneous motor and sensory restoration in three people with complete spinal cord injuries using patterned electrical stimulation and machine learning.
U: The Mind Company began taking orders for a consumer neuromodulation device on March 18, marketing bold clinical claims that have not appeared in peer-reviewed literature. An FDA submission is planned for 2027.
The Swedish company's FL-100 headset, cleared via the FDA's most stringent PMA pathway, launches in the US in Q2 2026 after a 174-person Nature Medicine trial. A second device, Neurolief's ProlivRx, was approved weeks later.
A UMC Utrecht study found that a brain-computer interface trained on daytime neural signals produced 245 false commands per hour when the patient slept, exposing a fundamental problem for 24/7 assistive devices.
The agency's new policy ending the two-trial requirement was written for drugs, but brain implant makers watching Synchron, Neuralink, and Paradromics navigate FDA are asking whether the same logic could eventually ease their path.
A new hafnium oxide memristor from the University of Cambridge mimics biological synapses with a million-fold reduction in switching current, pointing toward more efficient neuromorphic hardware.
A Health Affairs analysis argues that CMS needs a dedicated coverage pathway for implantable BCIs before the technology outpaces the reimbursement system that patients depend on.
NeuCyber Neurotech's rotating CEO concedes a significant technology gap with Musk's outfit, even as China pours state funding into catching up and expanding human trials to 50 patients.
The Ministry of Science and ICT has designated brain-computer interfaces as a core future industry, setting seven mission areas from paralysis treatment to defence applications, with full-scale project funding beginning in 2027.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.